Browsing Tag
Idiopathic pulmonary fibrosis
18 posts
Redx Pharma gets $9m as AstraZeneca initiates AZD5055 phase 1 trial
UK-based biotech company Redx Pharma said that it has received a milestone payment of $9 million from AstraZeneca…
Glenmark Pharmaceuticals gets FDA approval for Nintedanib Capsules
Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA)…
Galecto raises $64m to develop fibrosis and cancer treatments
Galecto, a Danish biotech company, has raised $64 million in an equity financing round, for developing novel treatments…
Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals
Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for…
Roche to acquire US biotech company Promedior for $1.4bn
Roche acquisition of Promedior : Swiss drugmaker Roche has agreed to acquire Massachusetts-based biotech company Promedior in a…
X-Rx announces FDA acceptance of IND for X-165, a potential treatment for Idiopathic Pulmonary Fibrosis
US-based biotech company X-Rx has received a major boost in its quest to develop new treatments for Idiopathic…
Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment
Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF)…
Roivant Sciences launches Respivant Sciences to advance treatments for respiratory diseases
Roivant Sciences has launched a new biopharma company, Respivant Sciences, to focus on cutting-edge treatments for severe respiratory…